Daniel Reker (D Reker)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 27

Top Venues

Nature reviews. Drug discovery

Nature computational science

Nature nanotechnology

Nature biomedical engineering

Duke University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Duke University Sep 01 2020

United States

Assistant Professor :: Biomedical Engineering

MIT Koch Institute for Integrative Cancer Research Apr 01 2016

United States

Postdoctoral Fellow

Publications

Zachary Fralish, Paul Skaluba, Daniel Reker
Leveraging bounded datapoints to classify molecular potency improvements. RSC medicinal chemistry 15 (7) (2024)
Zachary Fralish, Ashley Chen, Shaharyar Khan, Pei Zhou, Daniel Reker
The landscape of small-molecule prodrugs. Nature reviews. Drug discovery 23 (5) (2024)
Bárbara B Mendes, Zilu Zhang, João Conniot, Diana Pacheco Sousa, João M J M Ravasco, Lauren A Onweller, Andżelika Lorenc, Tiago Rodrigues, Daniel Reker, João Conde
A large-scale machine learning analysis of inorganic nanoparticles in preclinical cancer research. Nature nanotechnology 19 (6) (2024)
Chloe Markey, Samuel Croset, Olivia Ruth Woolley, Can Martin Buldun, Christian Koch, Daniel Koller, Daniel Reker
Characterizing emerging companies in computational drug development. Nature computational science 4 (2) (2024)
Zachary Fralish, Ashley Chen, Shaharyar Khan, Pei Zhou, Daniel Reker
The landscape of small-molecule prodrugs. Nature reviews. Drug discovery 23 (5) (2024)
Zachary Fralish, Ashley Chen, Shaharyar Khan, Pei Zhou, Daniel Reker
The landscape of small-molecule prodrugs. Nature reviews. Drug discovery (2024)
Yunhua Shi, Daniel Reker, James D Byrne, Ameya R Kirtane, Kaitlyn Hess, Zhuyi Wang, Natsuda Navamajiti, Cameron C Young, Zachary Fralish, Zilu Zhang, Aaron Lopes, Vance Soares, Jacob Wainer, Thomas von Erlach, Lei Miao, Robert S Langer, Giovanni Traverso
Screening oral drugs for their interactions with the intestinal transportome via porcine tissue explants and machine learning. Nature biomedical engineering 8 (3) (2024)
Bárbara B Mendes, Zilu Zhang, João Conniot, Diana Pacheco Sousa, João M J M Ravasco, Lauren A Onweller, Andżelika Lorenc, Tiago Rodrigues, Daniel Reker, João Conde
A large-scale machine learning analysis of inorganic nanoparticles in preclinical cancer research. Nature nanotechnology (2024)
Zachary Fralish, Paul Skaluba, Daniel Reker
Leveraging bounded datapoints to classify molecular potency improvements. RSC medicinal chemistry 15 (7) (2024)
Bárbara B Mendes, Zilu Zhang, João Conniot, Diana Pacheco Sousa, João M J M Ravasco, Lauren A Onweller, Andżelika Lorenc, Tiago Rodrigues, Daniel Reker, João Conde
A large-scale machine learning analysis of inorganic nanoparticles in preclinical cancer research. Nature nanotechnology 19 (6) (2024)
Yunhua Shi, Daniel Reker, James D Byrne, Ameya R Kirtane, Kaitlyn Hess, Zhuyi Wang, Natsuda Navamajiti, Cameron C Young, Zachary Fralish, Zilu Zhang, Aaron Lopes, Vance Soares, Jacob Wainer, Thomas von Erlach, Lei Miao, Robert S Langer, Giovanni Traverso
Screening oral drugs for their interactions with the intestinal transportome via porcine tissue explants and machine learning. Nature biomedical engineering 8 (3) (2024)
Yunhua Shi, Daniel Reker, James D Byrne, Ameya R Kirtane, Kaitlyn Hess, Zhuyi Wang, Natsuda Navamajiti, Cameron C Young, Zachary Fralish, Zilu Zhang, Aaron Lopes, Vance Soares, Jacob Wainer, Thomas von Erlach, Lei Miao, Robert S Langer, Giovanni Traverso
Screening oral drugs for their interactions with the intestinal transportome via porcine tissue explants and machine learning. Nature biomedical engineering (2024)
Zachary Fralish, Ashley Chen, Shaharyar Khan, Pei Zhou, Daniel Reker
The landscape of small-molecule prodrugs. Nature reviews. Drug discovery 23 (5) (2024)
Chloe E Markey, Daniel Reker
Machine learning trims the peptide drug design process to a sweet spot. Nature chemistry (2024)
Zachary Fralish, Ashley Chen, Shaharyar Khan, Pei Zhou, Daniel Reker
The landscape of small-molecule prodrugs. Nature reviews. Drug discovery (2024)
Chloe Markey, Samuel Croset, Olivia Ruth Woolley, Can Martin Buldun, Christian Koch, Daniel Koller, Daniel Reker
Characterizing emerging companies in computational drug development. Nature computational science 4 (2) (2024)
Chloe Markey, Samuel Croset, Olivia Ruth Woolley, Can Martin Buldun, Christian Koch, Daniel Koller, Daniel Reker
Characterizing emerging companies in computational drug development. Nature computational science 4 (2) (2024)
Zachary Fralish, Daniel Reker
Finding the most potent compounds using active learning on molecular pairs. Beilstein journal of organic chemistry 20 (2024)
Zachary Fralish, Ashley Chen, Shaharyar Khan, Pei Zhou, Daniel Reker
The landscape of small-molecule prodrugs. Nature reviews. Drug discovery 23 (5) (2024)
Chloe Markey, Samuel Croset, Olivia Ruth Woolley, Can Martin Buldun, Christian Koch, Daniel Koller, Daniel Reker
Characterizing emerging companies in computational drug development. Nature computational science 4 (2) (2024)
Michael W Mullowney, Katherine R Duncan, Somayah S Elsayed, Neha Garg, Justin Johan Jozias van der Hooft, Nathaniel I Martin, David Meijer, Barbara R Terlouw, Friederike Biermann, Kai Blin, Janani Durairaj, Marina Gorostiola González, Eric J N Helfrich, Florian Huber, Stefan Leopold-Messer, Kohulan Rajan, Tristan de Rond, Jeffrey A van Santen, Maria Sorokina, Marcy J Balunas, Mehdi A Beniddir, Doris A van Bergeijk, Laura M Carroll, Chase M Clark, Djork-Arné Clevert, Chris A Dejong, Chao Du, Scarlet Ferrinho, Francesca Grisoni, Albert Hofstetter, Willem Jespers, Olga V Kalinina, Satria A Kautsar, Hyun Woo Kim, Tiago F Leao, Joleen Masschelein, Evan R Rees, Raphael Reher, Daniel Reker, Philippe Schwaller, Marwin Segler, Michael A Skinnider, Allison S Walker, Egon L Wilighagen, Barbara Zdrazil, Nadine Ziemert, Rebecca J M Goss, Pierre Guyomard, Andrea Volkamer, William H Gerwick, Hyun Uk Kim, Daniel Krug, Gilles P van Wezel, Gerard van Westen, Anna Katharina Herta Hirsch, Roger G Linington, Serina L Robinson, Marnix H Medema
Artificial intelligence for natural product drug discovery. Nature reviews. Drug discovery (2023)
Yan Xiang, Yu-Hang Tang, Guang Lin, Daniel Reker
Interpretable Molecular Property Predictions Using Marginalized Graph Kernels. Journal of chemical information and modeling (2023)
Daniel Reker, Yulia Rybakova, Ameya R Kirtane, Ruonan Cao, Jee Won Yang, Natsuda Navamajiti, Apolonia Gardner, Rosanna M Zhang, Tina Esfandiary, Johanna L'Heureux, Thomas von Erlach, Elena M Smekalova, Dominique Leboeuf, Kaitlyn Hess, Aaron Lopes, Jaimie Rogner, Joy Collins, Siddartha M Tamang, Keiko Ishida, Paul Chamberlain, DongSoo Yun, Abigail K R Lytton-Jean, Christian K Soule, Jaime H Cheah, Alison M Hayward, Robert S Langer, Giovanni Traverso
Computationally guided high-throughput design of self-assembling drug nanoparticles. Nature nanotechnology 16 (6) (2021)
Daniel Reker, Steven M Blum, Christoph Steiger, Kevin E Anger, Jamie M Sommer, John Fanikos, Giovanni Traverso
"Inactive" ingredients in oral medications. Science translational medicine 11 (483) (2020)
Daniel Reker, Gonçalo J L Bernardes, Tiago Rodrigues
Computational advances in combating colloidal aggregation in drug discovery. Nature chemistry 11 (5) (2019)
Li Li, Gene Ching Chiek Koh, Daniel Reker, J B Brown, Haishuai Wang, Nicholas Keone Lee, Hien-Haw Liow, Hao Dai, Huai-Meng Fan, Luonan Chen, Dong-Qing Wei
Predicting protein-ligand interactions based on bow-pharmacological space and Bayesian additive regression trees. Scientific reports 9 (1) (2019)
Daniel Reker, P Schneider, G Schneider
Multi-objective active machine learning rapidly improves structure-activity models and reveals new protein-protein interaction inhibitors. Chemical science 7 (6) (2016)

Daniel Reker.css-eqlu8i{font-size:small;padding-left:4px;} (D Reker)

Publication Activity (10 Years)

Top Topics

Top Venues

Daniel Reker (D Reker)